TB-500
A 43-amino-acid peptide identical to naturally occurring thymosin beta-4 that promotes cell migration, wound healing, and tissue repair.
Also known as: Thymosin Beta-4, Tβ4, TB4
Regulatory Status
Classification date: 2026-02-27
Reclassification to Category 1 announced but not yet formalized
Compounding: Not currently available for compounding
Evidence Summary
How It Works
TB-500 is a synthetic version of thymosin beta-4, an actin-sequestering protein found in nearly all human cells. It promotes cell migration by upregulating actin polymerization, enabling cells to move through damaged tissue for repair. It also reduces inflammation, inhibits apoptosis, and promotes angiogenesis. In cardiac tissue, it has demonstrated the ability to activate resident progenitor cells and reduce scar formation after myocardial infarction in preclinical models.
Common Applications
Safety & Considerations
Generally well tolerated in clinical studies. Side effects are rare and may include head rush, mild nausea, or temporary lethargy. Theoretical concern that TB-500 could promote growth of existing tumors due to its angiogenic and cell-migration properties, though no direct evidence supports this. Currently not legal for compounding in the US.
Related Research
Regulatory classifications can change rapidly. The information shown here was last verified on 2026-02-27. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.